This morning Angle reported initial results from its two lead clinical trials with Parsortix, a liquid biopsy system. The two studies ran in parallel in Europe (ANG-001) and the US (ANG-003) and explored Parsortix’s efficacy in triaging women with ovarian masses before surgery ie looking at whether the tumour is benign or malignant to estimate the extent of the necessary surgery. Both studies recruited 200 patients each and reported sensitivity was up to 95%, while specificity was much higher than existing tests. Angle has refrained from releasing further data, as it believes that the diagnostic algorithms (combining Parsortix findings, RNA markers and patient data) that were developed during the trials could be patented.
Written by
Angle |
Milestone in ovarian cancer application |
Parsortix clinical trial results |
Pharma & biotech |
5 July 2017 |
Share price performance
Business description
Analyst
Angle is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||
This morning Angle reported initial results from its two lead clinical trials with Parsortix, a liquid biopsy system. The two studies ran in parallel in Europe (ANG-001) and the US (ANG-003) and explored Parsortix’s efficacy in triaging women with ovarian masses before surgery ie looking at whether the tumour is benign or malignant to estimate the extent of the necessary surgery. Both studies recruited 200 patients each and reported sensitivity was up to 95%, while specificity was much higher than existing tests. Angle has refrained from releasing further data, as it believes that the diagnostic algorithms (combining Parsortix findings, RNA markers and patient data) that were developed during the trials could be patented.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
04/13 |
0.97 |
(0.65) |
(1.61) |
0.0 |
N/A |
N/A |
04/14 |
0.00 |
(2.04) |
(2.39) |
0.0 |
N/A |
N/A |
04/15 |
0.00 |
(3.55) |
(7.50) |
0.0 |
N/A |
N/A |
04/16 |
0.36 |
(5.03) |
(7.97) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, share-based payments.
The next step is for the test to be optimised, as Angle believes some modifications to the analysis technique could improve performance still further. It will then seek to conduct validation studies to get the CE mark and FDA approval. The update on the further strategy is broadly in line with our expectations, although specific timelines for the validation studies are yet to be clarified. Notably, triaging is just part of the potential in ovarian cancer application. Parsortix captures circulating tumour cells and allows gene expression analysis to determine whether the tumour is malignant. The gene expression, however, could eventually also be used to select the most effective drugs. This would be highly desirable with neoadjuvant chemotherapy for example, when the drugs are given before the surgery. In general, gene expression profiling is widely perceived as one of the major tools for personalised medicine in the future.
Of the three potential clinical applications, using Parsortix for ovarian cancer is the most advanced. The two current studies followed the original report by the Medical University of Vienna in January 2015, when the researchers reported “unprecedented sensitivity and specificity” in the first small trial in ovarian cancer. The best-studied serum biomarker for ovarian cancer, CA-125, is elevated in c 85% of women with advanced ovarian cancer but its sensitivity is only c 50% in early-stage disease and the specificity is poor, meaning that serum levels are raised in a number of benign conditions and other cancers, as detailed in our outlook note. The FDA-approved OVA1 (Vermillion) is a blood test and software algorithm used to evaluate ovarian masses for malignancy before surgery. OVA1 has a sensitivity of c 92% but a specificity of just c 54%, resulting in a significant level of false positives, which results in women often being ‘over-diagnosed‘ and leading to ‘over-preparation’ for the surgery.
|
Disclaimer
|
|
Disclaimer
|
Research: Industrials
Cohort’s earnings performance in FY17 once again exceeded our expectations. Stronger performances from EID and MCL more than outweighed the sharp contraction at SCS, where a swift response from management has already improved profitability. The cash performance was also better than expected and the dividend increase to 7.1p was also ahead of our forecast. We expect further solid progress in the current year, and our fair value estimate currently stands at 471p.